SMARCB1 and chordoma: Mechanically, explaining the molecular mechanism and potential role of transcriptional inhibition and immunologic responses to SMARCB1/INI1-negative PDC will be available for preclinical experiments and clinical trials and lead to new therapeutic opportunities for chordoma patients.